000285052 001__ 285052
000285052 005__ 20240229155100.0
000285052 0247_ $$2doi$$a10.3390/cancers15205022
000285052 0247_ $$2pmid$$apmid:37894389
000285052 0247_ $$2pmc$$apmc:PMC10605854
000285052 0247_ $$2altmetric$$aaltmetric:155472978
000285052 037__ $$aDKFZ-2023-02195
000285052 041__ $$aEnglish
000285052 082__ $$a610
000285052 1001_ $$aHoeltgen, Line$$b0
000285052 245__ $$aProton Therapy for Advanced Juvenile Nasopharyngeal Angiofibroma.
000285052 260__ $$aBasel$$bMDPI$$c2023
000285052 3367_ $$2DRIVER$$aarticle
000285052 3367_ $$2DataCite$$aOutput Types/Journal article
000285052 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1698678277_32012
000285052 3367_ $$2BibTeX$$aARTICLE
000285052 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285052 3367_ $$00$$2EndNote$$aJournal Article
000285052 500__ $$a#EA:E050#
000285052 520__ $$aTo provide the first report on proton radiotherapy (PRT) in the management of advanced nasopharyngeal angiofibroma (JNA) and evaluate potential benefits compared to conformal photon therapy (XRT).We retrospectively reviewed 10 consecutive patients undergoing PRT for advanced JNA in a definitive or postoperative setting with a relative biological effectiveness weighted dose of 45 Gy in 25 fractions between 2012 and 2022 at the Heidelberg Ion Beam Therapy Center. Furthermore, dosimetric comparisons and risk estimations for short- and long-term radiation-induced complications between PRT plans and helical XRT plans were conducted.PRT was well tolerated, with only low-grade acute toxicities (CTCAE I-II) being reported. The local control rate was 100% after a median follow-up of 27.0 (interquartile range 13.3-58.0) months. PRT resulted in considerable tumor shrinkage, leading to complete remission in five patients and bearing the potential to provide partial or complete symptom relief. Favorable dosimetric outcomes in critical brain substructures by the use of PRT translated into reduced estimated risks for neurocognitive impairment and radiation-induced CNS malignancies compared to XRT.PRT is an effective treatment option for advanced JNA with minimal acute morbidity and the potential for reduced radiation-induced long-term complications.
000285052 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000285052 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000285052 650_7 $$2Other$$aNTCP
000285052 650_7 $$2Other$$ajuvenile nasopharyngea angiofibroma (JNA)
000285052 650_7 $$2Other$$alate effects
000285052 650_7 $$2Other$$aneurocognitive impairment
000285052 650_7 $$2Other$$apediatry
000285052 650_7 $$2Other$$aproton radiotherapy
000285052 650_7 $$2Other$$aradiotherapy
000285052 650_7 $$2Other$$asecondary cancers
000285052 7001_ $$0P:(DE-He78)b907c008f5a279f1f3539ca77ec858dc$$aTessonnier, Thomas$$b1$$eFirst author$$udkfz
000285052 7001_ $$00000-0001-7087-9581$$aMeixner, Eva$$b2
000285052 7001_ $$0P:(DE-He78)a8a8a2fe0df558db50514c1b568ca8ff$$aHoegen, Philipp$$b3$$udkfz
000285052 7001_ $$aKim, Ji-Young$$b4
000285052 7001_ $$aDeng, Maximilian$$b5
000285052 7001_ $$aSeidensaal, Katharina$$b6
000285052 7001_ $$aHeld, Thomas$$b7
000285052 7001_ $$aHerfarth, Klaus$$b8
000285052 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b9$$udkfz
000285052 7001_ $$00000-0003-1195-7150$$aHarrabi, Semi$$b10
000285052 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers15205022$$gVol. 15, no. 20, p. 5022 -$$n20$$p5022$$tCancers$$v15$$x2072-6694$$y2023
000285052 909CO $$ooai:inrepo02.dkfz.de:285052$$pVDB
000285052 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b907c008f5a279f1f3539ca77ec858dc$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000285052 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a8a2fe0df558db50514c1b568ca8ff$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000285052 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000285052 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000285052 9141_ $$y2023
000285052 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000285052 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000285052 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000285052 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-31T16:07:06Z
000285052 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000285052 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000285052 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000285052 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000285052 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000285052 980__ $$ajournal
000285052 980__ $$aVDB
000285052 980__ $$aI:(DE-He78)E050-20160331
000285052 980__ $$aI:(DE-He78)HD01-20160331
000285052 980__ $$aUNRESTRICTED